GlassScriptPhysician profile
Ibrahim A Munkaila
NPI 1346236114
$573.70
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $155 · 2021: $71.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $107.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $94.62 | 2019 | |
| Vifor Pharma, INC. | $73.24 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $62.59 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.96 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.08 | 2019-2021 | |
| Novo Nordisk INC | $24.92 | 2019 | |
| Merck Sharp & Dohme LLC | $23.57 | 2021 | |
| Pfizer INC. | $18.58 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.90 | 2019 | |
| Boston Scientific Corporation | $17.32 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $15.21 | 2020 | |
| Mylan Specialty L.P. | $11.43 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Munkaila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.